Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response
Akito Nakamura, Takahito Hara(Takeda (Japan)), Osamu Kurasawa(Takeda (Japan)), Ryuichi Nishigaki(Takeda (Japan)), Chisato Takahara(Takeda (Japan)), Yasuko Tsuchiya(Takeda (Japan)), Daisuke Tomita(Takeda (Japan)), Tadahiro Nambu(Takeda (Japan)), Yuka Hasegawa(Kyoto Prefectural University of Medicine), Ayumi Ando(Takeda (Japan)), Akito Hata(Takeda (United States)), Jun Fujimoto(Takeda (Japan)), Yoshinori Satomi(Takeda (Japan)), Kosei Toyoshima(Takeda (Japan)), Shunsuke Ebara(Takeda (Japan))
Cited by 172
Related Papers
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
|PubMed|2003|427
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
|Bioorganic & Medicinal Chemistry|2011|126
Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
|The Journal of Steroid Biochemistry and Molecular Biology|2012|116
Androgen Receptor and Invasion in Prostate Cancer
|Cancer Research|2008|115
Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer
|Clinical Cancer Research|2010|82